Northern Trust Corp Purchases 113,953 Shares of Fresenius Medical Care AG (NYSE:FMS)

Northern Trust Corp lifted its position in Fresenius Medical Care AG (NYSE:FMS) by 45.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 362,190 shares of the company’s stock after purchasing an additional 113,953 shares during the quarter. Northern Trust Corp owned about 0.06% of Fresenius Medical Care worth $8,200,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in FMS. Franklin Resources Inc. grew its position in Fresenius Medical Care by 3.3% in the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock worth $1,490,000 after acquiring an additional 2,386 shares in the last quarter. JPMorgan Chase & Co. grew its position in Fresenius Medical Care by 18.2% in the third quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock worth $211,000 after acquiring an additional 1,528 shares in the last quarter. Crossmark Global Holdings Inc. grew its position in Fresenius Medical Care by 2.2% in the fourth quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company’s stock worth $1,456,000 after acquiring an additional 1,398 shares in the last quarter. Blue Trust Inc. grew its position in Fresenius Medical Care by 15.6% in the fourth quarter. Blue Trust Inc. now owns 14,876 shares of the company’s stock worth $317,000 after acquiring an additional 2,013 shares in the last quarter. Finally, DAVENPORT & Co LLC grew its position in Fresenius Medical Care by 1.5% in the fourth quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company’s stock worth $1,316,000 after acquiring an additional 862 shares in the last quarter. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care Stock Up 1.3%

Shares of NYSE:FMS opened at $28.76 on Monday. Fresenius Medical Care AG has a 1 year low of $17.93 and a 1 year high of $28.80. The business has a 50 day simple moving average of $24.98 and a two-hundred day simple moving average of $23.73. The firm has a market capitalization of $16.87 billion, a PE ratio of 23.77, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.

Fresenius Medical Care (NYSE:FMS) last announced its earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.01. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. The business had revenue of $5.54 billion during the quarter, compared to analyst estimates of $4.71 billion. On average, equities analysts predict that Fresenius Medical Care AG will post 1.51 EPS for the current year.

Fresenius Medical Care Increases Dividend

The business also recently declared an annual dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 23rd will be paid a dividend of $0.7871 per share. This represents a dividend yield of 1.9%. The ex-dividend date is Friday, May 23rd. This is an increase from Fresenius Medical Care’s previous annual dividend of $0.44. Fresenius Medical Care’s payout ratio is currently 49.11%.

Analysts Set New Price Targets

Several research analysts recently commented on FMS shares. Truist Financial lifted their price target on Fresenius Medical Care from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Monday, May 12th. StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.